罗欣药业：11月28日召开董事会会议

Group 1 - The core point of the article is that Luoxin Pharmaceutical (SZ 002793) announced a board meeting to discuss the adjustment of the employee stock ownership plan for 2024, indicating ongoing corporate governance and strategic planning efforts [1] - For the first half of 2025, Luoxin Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 88.11%, pharmaceutical commerce for 10.1%, and other businesses for 1.79%, highlighting the company's strong focus on its core pharmaceutical manufacturing segment [1] - As of the report, Luoxin Pharmaceutical has a market capitalization of 5.9 billion yuan, reflecting its position in the market [1]